الفهرس Only 14 pages are availabe for public view
 |  | from | 157 |  |  |
| | | from | 157 | | |
Abstract
The present study has been conducted with two objectives in mind; first is to detect if there is a role for Thrombin-Activatable Fibrinolysis Inhibitor, TAFI (a new potent inhibitor of fibrinolysis) in the pathogenesis and progression of diabetic nephropathy and to clarify some of factors that might be responsible-among others- for the vulnerability of patients with diabetic nephropathy to the high morbidity and mortality that has been reported in these patients. Second is to find whether TAFI level in patients dialyzed due to diabetic nephropathy is affected or not by the modality of dialysis and thereby influences cardiovascular morbidity among these patients.
Forty type 2 diabetic patients in different stages of diabetic nephropathy were studied. They comprised four groups according to stage of diabetic nephropathy and according to modality of dialysis in those reaching ESRD; 10 type 2 diabetics in microalbuminuric stage, 10 type 2 diabetics in macroalbuminuric stage, 10 type 2 diabetic in end stage renal disease on regular hemodialysis, and 10 type 2 diabetic in end stage renal disease on regular peritoneal dialysis. In addition, 10 type 2 non-renal normotensive diabetic cases served as controls.